KURA•globenewswire•
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
Summary
– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML –
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 11, 2026 by globenewswire